No 13 (2013)

The article discusses the results of studies of drugs for the treatment of acute heart failure (AHF). The focus is on drug serelaxin (recombinant analogue of human relaxin-2), which is a promising drug for first-line treatment of AHF, allows to relief symptoms and improve clinical outcomes. Results of the study were the basis for assigning the expedited review status for registration of serelaxin in the Food and Drug Administration.

The article deals with current issues of pharmacotherapy of cardiovascular diseases, which are based on dysfunction of the renin-angiotensin-aldosterone system. The efficacy and safety of two major classes of drug therapy for cardiovascular diseases -sartans and angiotensin converting enzyme inhibitors - are compared; evidence-based data on both classes of drugs are presented.

This review is aimed to the presentation of results of modern studies, which demonstrate the efficacy, safety and tolerability of lornoxicam in patients with pain of various etiologies, or provide a comparative evaluation of lornoxicam with other drugs used in the treatment of acute and chronic pain.

In ischemia, metabolism of myocardium is characterized by abnormal transition to preferential consumption of glucose as an energy source. This process results in activation of в-oxidation of fatty acids, which leads to undue consumption of oxygen, accumulation of toxic metabolites with prooxidant properties, and damage of cardiomyocytes. Trimetazidine, preparation with metabolic action, blocks the β-oxidation of fatty acids and provides energy-saving, anti-ischemic and anti-oxidant activities, and therefore is recommended for the wide use in cardiological practice.

The article presents the modern approach to the selection of two-component antihypertensive combinations in different clinical settings for the treatment of arterial hypertension. The advantages and indications for the use of combination of angiotensin-converting enzyme (ACE) inhibitor with a dihydropyridine calcium channel blocker are discussed. The results of prospective studies demonstrating the efficacy and safety of a combination of a third generation calcium channel blocker lercanidipine and ACE inhibitor enalapril are presented.

Article is devoted to a problem of cognitive impairment against the background of arterial hypertension, and potentials for the use of antihypertensive therapy for their correction. Data of own research on the effect of amlodipine, third generation dihydropyridine calcium antagonist, on level of blood pressure and cognitive functions at elderly patients with an 1 degree arterial hypertension are presented. It is shown that according data both on routine blood pressure measurements and 24-hour blood pressure monitoring, this drug has high anti-hypertensive effect. The results of study indicate that amlodipine improves a series of the parameters of cognitive functions. Key words: arterial hypertension, antihypertensive therapy, cognitive functions, calcium blocker, amlodipine

The article discusses the mechanisms of cardioprotection of trimetazidine and its analogue Trimektal MR in patients with cardiovascular diseases. The role of drugs with metabolic action in the treatment of patients with various forms of coronary artery disease - from stable angina to acute coronary syndrome, with options for coronary intervention (prevention of reperfusion syndrome) is emphasized. Antianginal efficacy of Trimektal MR in the treatment of patients with functional class III stable angina is presented.

Sufficient magnesium concentration in the body is essential for the health. It is known that preparations based on magnesium salts of organic acids, in which the acid anion is a «carrier» of magnesium into cells, are characterized by high bioavailability. At the same time, these anions- carriers may also have their own «target» effects, also important for the maintenance of various systems of the human body. The article presents the results of the first chemoinformation analysis of orotic acid (OA) molecule. Similarities of orotate with a number of molecules of human metabolome and with various drugs were found. The results of the analysis in part explain the effectiveness of magnesium orotate in cardiological patients, which is well-known from clinical practice. Cardioprotective effects of OA may be realized by the regulation of the N-acetylglucosamin transferase, inhibition of phosphodiesterases, the regulation of the effects of PQQ coenzyme and, probably, anti-inflammatory action. In addition, the results of the chemoinformation analysis indicate antioxidant, immunomodulating, neuroprotective properties of OA, which currently remain largely unexplored. Thus, the results indicate that OA is independent active substance synergistic to magnesium, and outline the prospects for further research on the use of magnesium orotate in clinical practice.

This study was aimed to the evaluation of clinical efficacy, tolerability and safety of artradol in patients with cervical spine dorsopathies. The comparative clinical evaluation of 90 patients aged from 35 to 70 years was performed. Patients were divided into two groups. Main group of patients received artradol in addition to standard therapy of dorsopathies; comparison group received standard therapy alone. The results of study allow to conclude that artradol has a positive effect on the dynamics of neurological manifestations, good tolerability and high efficacy.

Acute and chronic pain syndromes, sleep disorders, and mood changes are the most frequent disorders associated with «office» lifestyle. These disorders significantly affect the quality of life and can cause disability. The article considers the basic neurological syndromes in business person, the criteria for their diagnosis and treatment guidelines.